Navigation Links
Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study
Date:10/11/2007

to analyze dose response.

In the first step of the statistical analysis, the high-dose teduglutide group was compared with the placebo group using a 0.05 significance level. If the high-dose group was not statistically significantly different from the placebo group, no further comparisons would be made. If the high-dose group showed statistical significance, comparisons were to continue to a second analysis step, where the low dose was to be compared with the placebo.

Phase 2 Proof-of-Concept Study Results

In the Phase 2 GATTEX proof-of-concept study, the drug was given by subcutaneous injection for 21 days to 16 patients with SBS. Three patients received 0.03 mg/kg/day, ten patients received 0.10 mg/kg/day, and three patients received 0.15 mg/kg/day. Results of the Phase 2 study indicated that GATTEX was safe and well-tolerated, resulted in intestinal epithelial regeneration and significantly increased intestinal absorption and body weight in parenteral-nutrition-dependent SBS patients.

About SBS

SBS is a condition resulting from the surgical removal of significant portions of the bowel following injury or illness. There are 16,000 to 20,000 adult patients with SBS in the United States. Regulatory authorities in the U.S. and European Union have granted orphan drug status to teduglutide for its potential use, if approved, in treating SBS. Symptoms of SBS include diarrhea, dehydration, malnourishment, and weight loss caused by an inadequate absorption of nutrients and fluids from the diet. Long-term complications of the condition may include an increased risk of systemic infections due to the presence of an intravenous feeding line, degenerative changes in the bones and nerves due to vitamin and mineral deficiencies, and liver failure. Potential benefits derived from reduced dependence on intravenous feeding may include improved nutrition, lower rates of infections, and improved quality of life due to more time away from intravenous feed
'/>"/>

SOURCE NPS Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
9. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... YORK , April 27, 2015 Harwood ... against the board of directors of Aerie Pharmaceuticals, Inc. ... whether the board has breached its fiduciary duties to ... issued a press release announcing results from its first ... the press release disclosed that in the trial, Rhopressa ...
(Date:4/27/2015)... YORK , April 27, 2015 Bronstein, ... behalf of purchasers of the securities of Celladon Corporation ... are advised to contact Peretz Bronstein or ... info@bgandg.com or 212-697-6484. The investigation ... directors have violated Sections 10(b) and 20(a) of the ...
(Date:4/27/2015)... 27, 2015  Eiger BioPharmaceuticals, Incorporated today announced the ... lonafarnib in patients with chronic hepatitis delta viral (HDV) ... enrolled at Ankara University Medical School, Turkey ... LOWR HDV - 1 (LOnafarnib With ... which randomized subjects to receive different doses of lonafarnib ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Aerie Pharmaceuticals, Inc. 2SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Celladon Corporation 2Eiger Bio Announces Interim Results of Lonafarnib in Combination with Ritonavir or Pegylated Interferon in Patients Infected with Hepatitis Delta Virus (HDV) 2Eiger Bio Announces Interim Results of Lonafarnib in Combination with Ritonavir or Pegylated Interferon in Patients Infected with Hepatitis Delta Virus (HDV) 3
... Inc. (Hologic or the Company) (NASDAQ: HOLX ... diagnostics products, medical imaging systems and surgical products dedicated ... the Company will host presentations for members of the ... North America) trade show in Chicago, IL. For more ...
... Ohio, Oct. 27, 2011 Mettler-Toledo International Inc. (NYSE: ... call to discuss the Company,s third-quarter results on Thursday, November ... live webcast of the call, visit www.mt.com/investors on ... available until November 7, 2011. METTLER TOLEDO ...
Cached Medicine Technology:Hologic to Host Investor Presentation at RSNA 2011 2
(Date:4/28/2015)... Santa Cruz, California (PRWEB) April 28, 2015 ... leader in premium, healthy, and convenient nutrition ... expansion of its distribution through United Natural ... distributor of natural, organic and specialty foods ... will now be available to thousands of ...
(Date:4/27/2015)... Churchview Supportive Living, a Gardant affordable ... and Fashion Show from 10:30 a.m. to noon on ... 2626 W. 63rd St. in Chicago, serves low-income older ... to maintain their independence. , “Mothers, grandmothers, godmothers and ... Day Brunch,” said Director of Marketing Elizabeth Clippard. , ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 Women may ... from concussion, according to a new study published online ... mild traumatic brain injury (MTBI), is a common medical ... some individuals. , In most cases, patients who ... Ten to 15 percent of MTBI patients will continue ...
(Date:4/27/2015)... 2015 Jesse L. Goodman, M.D., M.P.H., ... Pharmacopeial Convention (USP) at the recently concluded Convention Meeting ... at Georgetown University and the Director of its Center ... As USP President, a volunteer position, Dr. Goodman will ... be a voting member, ex officio, of the Board ...
(Date:4/27/2015)... 27, 2015 Based in the Twin ... one of the few insurance marketing organizations in the ... and asset protection markets as well as employer sponsored ... afforded Secura Consultants the opportunity to consult with disability ... business easier and quicker. , An example of these ...
Breaking Medicine News(10 mins):Health News:LifeAID Beverage Co. Announces Expanded Distribution Roll Out Through UNFI -- United Natural Foods Inc. 2Health News:LifeAID Beverage Co. Announces Expanded Distribution Roll Out Through UNFI -- United Natural Foods Inc. 3Health News:Churchview Supportive Living Community in Chicago to Host Mother's Day Brunch 2Health News:Women Show Persistent Memory Impairment after Concussion 2Health News:Women Show Persistent Memory Impairment after Concussion 3Health News:Dr. Jesse Goodman Elected President of the USP Convention 2Health News:Simplified Solutions Now Makes Disability Insurance Business With Secura Consultants Even Easier! 2
... A recent research has found that the asthma epidemic in ... by adults over the past century . ,The study, ... is published this month in Annals of Allergy, Asthma & ... Asthma and Immunology (ACAAI). ,The pervasiveness of asthma ...
... a woman's reproductive history to start hormone therapy? How does ... is the most beneficial form of estrogen? ,These ... University of Wisconsin School of Medicine and Public Health hope ... of its kind, on the effects of estrogen therapy with ...
... tests using gene sequencing is able to help confirm ... the tools for much more accurate and rapid diagnosis. ... 40 inherited and potentially life-threatening disorders that cause enzymes ... to the accumulation of waste products that damage organs ...
... College London refutes the long-standing "runaway" theory on how HIV ... attacking T helper cells, a class of white blood cells ... long been puzzled as to why this process of depletion ... ,According to the "runaway" hypothesis, T cells infected ...
... documented the first case of virgin birth in cartilaginous fish, after ... aquarium, that had only female sharks which had no contact ... of the pup at Omaha's Henry Doorly Zoo, in the US, ... in one of the female sharks in the aquarium. ...
... Club of Calcutta will reach out to more poor people ... ,"All the three healthcare units we have opened in ... set a target to reach out to more number of ... functionary K.N. Gupta told a press conference Tuesday. ...
Cached Medicine News:Health News:Rise in Cigarette Use may Elucidate Asthma Epidemic in Children 2Health News:Effectiveness of Hormone Therapy During Menopause 2Health News:New DNA Tests Advances Treatment of Lysosomal Storage Diseases 2Health News:Study Refutes Theory on HIV's Effect on White Blood Cells 2
... and Respiratory Products, ,Westmed designs, manufacturers ... Anesthesia and Respiratory professionals. Our mission is ... the clinician's ability to deliver quality medical ... bottom line. , ,Our web site ...
... FISH pharmDx Kit is a direct fluorescence ... quantitatively determine HER2 gene amplification in formalin-fixed, ... is determined from the ratio between the ... the HER2 gene probe (red signals) and ...
... PathVysion is the only HER-2 assessment test ... Administration (FDA) for three claims: prognosis, adriamycin-based ... therapy selection. PathVysion is the only FISH-based ... Herceptin® package insert as an appropriate test ...
... Products, ,Westmed designs, manufacturers and markets ... Respiratory professionals. Our mission is to design ... ability to deliver quality medical care while ... , ,Our web site is designed ...
Medicine Products: